A three-year study by Metropolis Healthcare reveals that 28.4 per cent of nearly 20,000 children screened for ...

Editas Medicine reports successful gene editing levels in stem cells, supporting potential treatment for sickle cell disease and beta thalassemia. Editas Medicine announced promising new data on ...

A new study reveals that over one in four Indian children under 12 carry inherited blood disorders. The findings highlight ...

Our Bureau, Bengaluru Wednesday, May 21, 2025, 16:15 Hrs [IST] ...

Two great examples are Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) and Vertex Pharmaceuticals (NASDAQ: VRTX). Warren ...

Beta Thalassemia and sickle cell disorders continue to be major health challenges in India, with Thalassemia being one of the most common inherited blood disorders. The condition results in a ...

Shares of CRISPR Therapeutics have lost momentum in recent years. Despite making significant clinical progress, CRISPR ...

In medical breakthrough, a baby diagnosed with rare genetic disorder is thriving after customized CRISPR gene editing therapy ...

With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to ...

G ene therapy has always held enormous promise to correct genetic diseases, but turning that potential into treatments has been challenging.

KJ Muldoon came into the world with a genetic time bomb ticking inside him.

Further, Editas Medicine has decreased expenses and costs thanks to discontinuing the development of reni-cel and laying off ...